ArticleDrug testing and analysis2025
Effects of the Dietary Supplement 5α-Hydroxy-Laxogenin in the Orchiectomized Rat Model.
Article in Drug testing and analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification of Metabolites of the Dietary Supplement Ingredient 5α-Hydroxy-Laxogenin.Drug testing and analysis · 2026Article
- Effects of the Dietary Supplement 5α-Hydroxy-Laxogenin in the Orchiectomized Rat Model.Drug testing and analysis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dietary supplements used by recreational and elite athletes for performance enhancement might contain undeclared, unlawfully added ingredients. One of those ingredients is 5α-hydroxy-laxogenin, which is sold in dietary supplements marketed as a natural compound with anabolic effects. It has been shown that 5α-hydroxy-laxogenin is not naturally occurring, but rather of synthetic origin. Previously, we observed that 5α-hydroxy-laxogenin can bind to and activate the androgen receptor in a cell-based bioassay. To investigate its androgenic potential in vivo, we treated orchiectomized rats with three different dosages of 5α-hydroxy-laxogenin for 2 weeks. Effects were neither observed on the wet weights of the androgen target tissues prostate, seminal vesicle or penis nor on the wet weights of the anabolic target tissue musculus levator ani or on skeletal hindlimb muscles. Au contraire, significantly higher atrophy was seen for some of the target tissues in the animals treated with the highest 5α-hydroxy-laxogenin dosage (36 mg/kg bw). While in silico docking supports the androgen receptor binding previously observed in vitro, we observed neither androgenic nor anabolic effects of 5α-hydroxy-laxogenin in vivo in castrated male rats.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.